José María Pelayo-Terán

José María Pelayo-Terán

Auto-generated profile, based on publicly available information

José María Pelayo-Terán

CIBER Salud Mental (CIBERSAM), Madrid, Spain; Servicio de Psiquiatría y Salud Mental. Hospital el Bierzo, Gerencia de Asistencia Sanitaria del Bierzo (GASBI). Gerencia Regional de Salud de Castilla y Leon (SACYL). Ponferrada, León, Spain; Area de Medicina Preventiva y Salud Pública. Universidad de León, León, Spain

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2020 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
MGMarcos Gómez-Revuelta
Marcos Gómez-Revuelta
JPJosé María Pelayo-Terán
José María Pelayo-Terán
MJMaría Juncal-Ruiz
María Juncal-Ruiz
JVJavier Vázquez-Bourgon
Javier Vázquez-Bourgon
PSPaula Suárez-Pinilla
Paula Suárez-Pinilla
BCBenedicto Crespo-Facorro
Benedicto Crespo-Facorro
Different effectiveness profiles among antipsychotics may be a key point to optimize treatment in patients suffering a first episode of psychosis to impact on long-term outcome. The aim of this study is to compare the clinical effectiveness of olanzapine, risperidone, haloperidol, aripiprazole, ziprasidone, and quetiapine in the treatment of first episode of psychosis at 3-year follow-up. From February 2001 to January 2011, 2 phases of a prospective, randomized, open-label study were undertaken. A total of 376 first-episode drug-naïve patients were randomly assigned to olanzapine (n = 55), risperidone (n = 63), haloperidol (n = 56), aripiprazole (n = 78), ziprasidone (n = 62), or quetiapine (n = 62) and followed up for 3 years. The primary effectiveness measure was all cause of treatment discontinuation. In addition, an analysis based on intention-to-treat principle was conducted in the analysis for clinical efficacy. The overall dropout rate at 3 years reached 20.75%. Treatment discontinuation rates were significantly different among treatment groups (olanzapine = 69.09, risperidone = 71.43, aripiprazole = 73.08%, ziprasidone = 79.03%, haloperidol = 89.28%, and quetiapine = 95.53%) (χ2 = 79.86; P = .000). Statistically significant differences in terms of lack of efficacy, adherence, and tolerability were observed among treatment groups along the 3-year follow-up, determining significant differences in time to all-cause discontinuation (log-rank = 92.240; P = .000). Significant differences between treatments were found in the categories of sleepiness/sedation, increased sleep duration, akinesia, weight gain, ejaculatory dysfunction, extrapyramidal-symptoms, and amenorrhea. Olanzapine, risperidone, and aripiprazole presented advantages for the first-line treatment of first episode of psychosis in terms of effectiveness. Identifying different discontinuation patterns may contribute to optimize treatment selection after first episode of psychosis. ClinicalTrials.gov Identifier: NCT02526030 https://clinicaltrials.gov/show/NCT02526030

28 October 2016 in European Archives of Psychiatry and Clinical Neuroscience
Verified
Journal Article
Closed access
PDF file
JPJosé María Pelayo-Terán
José María Pelayo-Terán
VGVirginia Gajardo Gajardo Galán
Virginia Gajardo Gajardo Galán
VFVíctor de la Ortiz-García de la Foz
Víctor de la Ortiz-García de la Foz
OMObdulia Martínez-García
Obdulia Martínez-García
RTRafael Tabarés-Seisdedos
Rafael Tabarés-Seisdedos
RARosa Ayesa-Arriola
Rosa Ayesa-Arriola

1 October 2018 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
RARosa Ayesa-Arriola
Rosa Ayesa-Arriola
JTJose María Pelayo Terán
Jose María Pelayo Terán
Javier-David Lopez-MorinigoJavier-David Lopez-Morinigo
Javier-David Lopez-Morinigo
MCManuel Canal-Rivero
Manuel Canal-Rivero
ESEsther Setién-Suero
Esther Setién-Suero
BCBenedicto Crespo-Facorro
Benedicto Crespo-Facorro

1 August 2018 in European Psychiatry
Verified
Journal Article
Closed access
JPJosé María Pelayo-Terán
José María Pelayo-Terán
VGVirginia Gajardo-Galán
Virginia Gajardo-Galán
MGMarcos Gómez-Revuelta
Marcos Gómez-Revuelta
VFVictor Ortiz-García de la Foz
Victor Ortiz-García de la Foz
RARosa Ayesa-Arriola
Rosa Ayesa-Arriola
BCBenedicto Crespo-Facorro
Benedicto Crespo-Facorro
Background: The duration of untreated psychosis (DUP) has been associated with negative outcomes in psychosis; however, few studies have focused on the duration of active psychotic symptoms after commencing treatment (DAT). In this study, we aimed to evaluate the effect of DUP and DAT on functional long-term outcomes (3 years) in patients with early psychosis.Methods: We evaluated the Scale for the Assessment of Positive Symptoms (SAPS) at frequent intervals for 3 years after presentation to determine the DAT for 307 individuals with first-episode psychosis together with DUP and clinical variables. The functional outcomes were assessed using the Disability Assessment Scale (DAS) at three years, and functional recovery was defined as minimal impairment and return to activity. Associated variables, DAT and DUP were included in logistic regression models to predict functional outcomes. Receiver operating characteristic curves and Youden’s index were applied to assess the best cut-off values.Results: DAT, (Wald: 13.974; ExpB: 1.097; p < 0.001), premorbid adjustment, initial BPRS score, gender, age of onset and schizophrenia diagnosis were significant predictors of social functioning, whereas only premorbid adjustment (Wald: 11.383; ExpB:1.009), DAT (Wald: 4.850; ExpB: 1.058; p = 0.028) and education were significant predictors of recovery. The optimal cut-off of DAT for predicting social functioning was 3.17 months for DAT (sensitivity: 0.68; specificity: 0.64; Youden’s index: 0.314).Conclusions: DAT is strongly related to functional outcomes independent of the DUP period or other variables. As a modifiable variable, the reduction of the DAT should be considered a main focus of intervention from the onset of the illness to improve long-term outcomes.

12 September 2018 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
MGMarcos Gómez-Revuelta
Marcos Gómez-Revuelta
JPJosé María Pelayo-Terán
José María Pelayo-Terán
MJMaría Juncal-Ruiz
María Juncal-Ruiz
VFVíctor Ortiz-García de la Foz
Víctor Ortiz-García de la Foz
JVJavier Vazquez-Bourgon
Javier Vazquez-Bourgon
BCBenedicto Crespo-Facorro
Benedicto Crespo-Facorro
Different effectiveness profiles among second-generation antipsychotics may be a key point to optimize treatment in patients suffering a first episode of psychosis to affect long-term outcome. The aim of this study was to compare the clinical effectiveness of aripiprazole, ziprasidone, and quetiapine in the treatment of first episode of psychosis at 3-year follow-up. From October 2005 to January 2011, a prospective, randomized, open-label study was undertaken. Two hundred-two first-episode, drug-naïve patients were randomly assigned to aripiprazole (n=78), ziprasidone (n =62), or quetiapine (n=62) and followed-up for 3 years. The primary effectiveness measure was all cause of treatment discontinuation. In addition, an analysis based on the intention-to-treat principle was conducted in the analysis for clinical efficacy. The overall dropout rate at 3 years reached 19.3%. Treatment discontinuation rates were significantly different among treatment groups (aripiprazole=73.08%, ziprasidone=79.03%, and quetiapine=95.16%) (χ2=11.680; P=.001). Statistically significant differences in terms of nonefficacy, nonadherence, and side effects were observed among treatment groups along the 3-year follow-up determining significant differences in time to all-cause discontinuation (log-rank=32.260; P=.001). Significant differences between treatments were found in the categories of sleepiness/sedation (χ2=9.617; P=.008) and increased sleep duration (χ2=6.192; P=.004). No significant differences were found in the profile of extrapyramidal symptoms. Patients on aripiprazole were more likely to be prescribed benzodiazepines. First-episode psychosis patients on quetiapine were more likely to discontinue treatment due to nonefficacy. Identifying different discontinuation patterns may contribute to optimize treatment selection after first episode of psychosis.

16 February 2024 in Psychiatry Research
Verified
Journal Article
Open access
PMPhilippe Mortier
Philippe Mortier
GVGemma Vilagut
Gemma Vilagut
HGHelena García-Mieres
Helena García-Mieres
IAItxaso Alayo
Itxaso Alayo
MFMontserrat Ferrer
Montserrat Ferrer
JAJordi Alonso
Jordi Alonso
Little is known about healthcare workers' (HCW) use of healthcare services for mental disorders. This study presents data from a 16-month prospective cohort study of Spanish HCW (n = 4,809), recruited shortly after the COVID-19 pandemic onset, and assessed at four timepoints using web-based surveys. Use of health services among HCW with mental health conditions (i.e., those having a positive screen for mental disorders and/or suicidal thoughts and behaviours [STB]) was initially low (i.e., 18.2 %) but increased to 29.6 % at 16-month follow-up. Service use was positively associated with pre-pandemic mental health treatment (OR=1.99), a positive screen for major depressive disorder (OR=1.50), panic attacks (OR=1.74), suicidal thoughts and behaviours (OR=1.22), and experiencing severe role impairment (OR=1.33), and negatively associated with being female (OR = 0.69) and a higher daily number of work hours (OR=0.95). Around 30 % of HCW with mental health conditions used anxiolytics (benzodiazepines), especially medical doctors. Four out of ten HCW (39.0 %) with mental health conditions indicated a need for (additional) help, with most important barriers for service use being too ashamed, long waiting lists, and professional treatment not being available. Our findings delineate a clear mental health treatment gap among Spanish HCW.